The stock of Juno Therapeutics Inc (NASDAQ:JUNO) gapped down by $7.23 today and has $21.66 target or 4.00% below today’s $22.56 share price. The 8 months technical chart setup indicates high risk for the $2.27 billion company. The gap down was reported on Nov, 24 by Barchart.com. If the $21.66 price target is reached, the company will be worth $90.80 million less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 24.50% or $7.32 on November 23, hitting $22.56. About 17.58 million shares traded hands or 1112.41% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 earnings per share, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 67% are positive. Juno Therapeutics Inc has been the topic of 20 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Friday, July 8 by FBR Capital. FBR Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Tuesday, August 18. FBR Capital has “Outperform” rating and $73 price target. As per Friday, August 5, the company rating was maintained by Maxim Group. The firm has “Mkt Perform” rating given on Wednesday, November 23 by FBR Capital. Standpoint Research initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Monday, August 24. Standpoint Research has “Buy” rating and $47.0 price target. JP Morgan downgraded Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, July 8. JP Morgan has “Neutral” rating and $39 price target. The rating was downgraded by Standpoint Research to “Hold” on Thursday, October 29. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) has “Outperform” rating given on Wednesday, July 22 by Northland Capital. Citigroup initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Thursday, February 25 with “Buy” rating. Goldman Sachs initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Wednesday, November 18 with “Neutral” rating.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Jpmorgan Chase & accumulated 0% or 4,774 shares. Apriem Advisors accumulated 0% or 300 shares. Mutual Of America Management Limited Liability Com last reported 0% of its portfolio in the stock. Moreover, Rockefeller Financial Services Inc has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 226 shares. Pittenger Anderson Incorporated last reported 0% of its portfolio in the stock. First Tru Advisors L P holds 0.09% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 703,197 shares. Schwab Charles Investment Mngmt holds 0.01% or 234,448 shares in its portfolio. Commonwealth Equity has 23,541 shares for 0.01% of their US portfolio. Bessemer Grp Inc owns 3,809 shares or 0% of their US portfolio. Alpine Woods Cap Investors Limited Liability Com accumulated 0.03% or 13,000 shares. Brick And Kyle Assoc accumulated 0.02% or 500 shares. Federated Invsts Pa owns 27,614 shares or 0% of their US portfolio. Panagora Asset Management accumulated 0% or 2,710 shares. Mariner Investment Ltd Limited Liability Company has invested 0.23% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Mycio Wealth Ptnrs Limited Liability Company reported 500 shares or 0% of all its holdings.
More important recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016, also Marketwatch.com published article titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …”, Nasdaq.com published: “Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics …” on November 23, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) was released by: Fool.com and their article: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.